Tian Dan, Yu Nianxi, Mao Tianxiao, Li Yanli, Liu Ruiyan, Xu Ye, Huang Dong, Lv Qianzhou, Pan Kunming
Department of Pharmacy, Zhongshan Hospital Fudan University, Shanghai, China.
Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Front Cardiovasc Med. 2025 Jul 10;12:1591578. doi: 10.3389/fcvm.2025.1591578. eCollection 2025.
This study aims to investigate the prognostic value of integrating inflammatory biomarkers with the established Global Registry of Acute Coronary Events (GRACE) risk score for predicting clinical outcomes in patients with myocardial infarction (MI).
This prospective, single-center study enrolled adult MI patients admitted to the coronary care unit at Zhongshan Hospital, Fudan University. Blood samples were collected to measure inflammatory markers (IL-1β, sIL-2R, IL-6, IL-8) and myocardial biomarkers. The Gensini score and GRACE score were calculated for each patient. The primary endpoint was the post-MI occurrence of a composite of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal MI, and non-fatal ischemic stroke. Predictive performance of biomarkers was evaluated using Kaplan-Meier survival curves, Cox regression analysis, and receiver operating characteristic (ROC) curves.
A total of 724 patients (median age 64 years, 85.0% male) were included with a median follow-up of 1.7 years. During follow-up, 81 patients (11.1%) experienced MACE, including 45 cardiovascular deaths, 23 MIs, and 13 strokes. Multivariate Cox regression analysis revealed that sIL-2R and IL-8 were independent predictors of MACE. Elevated levels of sIL-2R (HR = 9.123, 95% CI: 5.883-14.147, < 0.001) and IL-8 (HR = 4.443, 95% CI: 2.769-7.131, < 0.001) were significantly associated with an increased risk of MACE. After adjustment for cardiovascular risk factors, elevated sIL-2R (adjusted HR: 3.761, 95% CI: 2.269-6.233, < 0.001) and IL-8 (adjusted HR: 2.294, 95% CI: 1.375-3.825, = 0.001) levels remained significantly associated with an increased risk of MACE. The combination of sIL-2R, IL-8, and GRACE score displayed effective predictive performance for long-term MACE, as evidenced by ROC curve analysis (AUC = 0.824, 95% CI: 0.775-0.873, < 0.001).
Elevated levels of sIL-2R and IL-8 independently predict increased risk of MACE in MI patients. Integrating biomarkers such as sIL-2R and IL-8 with the GRACE score can significantly improve predictive performance, offering a robust approach for risk stratification in MI patients.
本研究旨在探讨整合炎症生物标志物与已建立的急性冠状动脉事件全球注册(GRACE)风险评分对预测心肌梗死(MI)患者临床结局的预后价值。
这项前瞻性单中心研究纳入了复旦大学附属中山医院冠心病监护病房收治的成年MI患者。采集血样以检测炎症标志物(IL-1β、可溶性白细胞介素-2受体[sIL-2R]、IL-6、IL-8)和心肌生物标志物。计算每位患者的Gensini评分和GRACE评分。主要终点是MI后发生的主要不良心血管事件(MACE)复合终点,包括心血管死亡、非致命性MI和非致命性缺血性卒中。使用Kaplan-Meier生存曲线、Cox回归分析和受试者工作特征(ROC)曲线评估生物标志物的预测性能。
共纳入724例患者(中位年龄64岁,85.0%为男性),中位随访时间为1.7年。随访期间,81例患者(11.1%)发生MACE包,括45例心血管死亡、23例MI和13例卒中。多变量Cox回归分析显示,sIL-2R和IL-8是MACE的独立预测因素。sIL-2R水平升高(风险比[HR]=9.123,95%置信区间[CI]:5.883-14.147,P<0.001)和IL-8水平升高(HR=4.443,95%CI:2.769-7.131,P<0.001)与MACE风险增加显著相关。在调整心血管危险因素后,sIL-2R水平升高(调整后HR:3.761,95%CI:2.269-6.233,P<0.001)和IL-8水平升高(调整后HR:2.294,95%CI:1.375-3.825,P=0.001)仍与MACE风险增加显著相关。ROC曲线分析表明,sIL-2R、IL-8和GRACE评分联合对长期MACE具有有效的预测性能(曲线下面积[AUC]=0.824,95%CI:0.775-0.873,P<0.001)。
sIL-2R和IL-8水平升高独立预测MI患者MACE风险增加。将sIL-2R和IL-8等生物标志物与GRACE评分相结合可显著提高预测性能,为MI患者的风险分层提供了一种可靠的方法。